Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802040 | 0.85 | ACE (0.52) | ACEAPLNROPRM1OPRK1F2 | |
| SCHEMBL30844396 | 0.84 | ACE (0.46) | ACEAPLNR | |
| SCHEMBL29801911 | 0.84 | ACE (0.52) | ACEF2 | |
| SCHEMBL30844328 | 0.83 | ACE (0.48) | ACEAPLNROPRK1 | |
| SCHEMBL29801838 | 0.83 | OPRM1 (0.52) | ACEAPLNROPRM1OPRK1 | |
| SCHEMBL29801966 | 0.83 | ACE (0.51) | ACEOPRK1 | |
| SCHEMBL29801988 | 0.83 | ACE (0.51) | ACEOPRK1F2 | |
| SCHEMBL29801916 | 0.83 | ACE (0.53) | ACEOPRM1F2 | |
| SCHEMBL29423403 | 0.82 | F2 (0.50) | ACEAPLNROPRM1F2 | |
| SCHEMBL31031600 | 0.82 | F2 (0.47) | ACEAPLNROPRM1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048988-A1 | CELLS EXPRESSING ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USING THE SAME | CHILDREN'S NATIONAL MEDICAL CENTER | 2022-02-17 | — | — | US | claimed |
| EP-4039710-B1 | ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 | SANOFI SA (FR) | 2026-03-25 | — | — | EP | disclosed |
| US-20250312475-A1 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | SANOFI (FR) | 2025-10-09 | — | — | US | disclosed |
| EP-4536676-A2 | METHODS FOR PURIFICATION OF MULTI-SPECIFIC ANTIBODIES | Sanofi (FR) | 2025-04-16 | — | — | EP | disclosed |
| CN-119343359-A | Method for purifying multispecific antibodies | 赛诺菲 | 2025-01-21 | — | — | CN | disclosed |
| CN-119291194-A | Method for quantifying a polypeptide | 建新公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-110256569-B | Dual variable region antibody-like binding proteins with exchange binding region orientation | 赛诺菲 | 2025-01-07 | — | — | CN | disclosed |
| CN-111801580-B | Method for quantifying a polypeptide | 建新公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240279362-A1 | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | SANOFI (FR) | 2024-08-22 | — | — | US | disclosed |
| CN-109476732-B | Trispecific and/or trivalent binding proteins | 赛诺菲 | 2024-03-22 | — | — | CN | disclosed |
| US-11739160-B2 | PseudoFab-based multispecific binding proteins | SANOFI (FR) | 2023-08-29 | — | — | US | disclosed |
| EP-3443006-B1 | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | SANOFI SA (FR) | 2023-08-02 | — | — | EP | disclosed |
| CN-109311966-B | Trispecific and/or trivalent binding proteins for use in the prevention or treatment of HIV infection | 赛诺菲 | 2023-03-10 | — | — | CN | disclosed |
| EP-4039710-A2 | ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123 | SANOFI (FR) | 2022-08-10 | — | — | EP | disclosed |
| CN-114885609-A | pseudo-Fab based multispecific binding proteins | 赛诺菲 | 2022-08-09 | — | — | CN | disclosed |
| US-20220226495-A1 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | SANOFI (FR) | 2022-07-21 | — | — | US | disclosed |
| US-20220119553-A1 | TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS | SANOFI (FR) | 2022-04-21 | — | — | US | disclosed |
| CN-114230668-A | anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123 | 赛诺菲 | 2022-03-25 | — | — | CN | disclosed |
| CN-114230667-A | anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123 | 赛诺菲 | 2022-03-25 | — | — | CN | disclosed |
| US-20220048988-A1 | CELLS EXPRESSING ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USING THE SAME | CHILDREN'S NATIONAL MEDICAL CENTER | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312475-A1 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | CD4, HAVCR2, TIMCC | ACE 4153/4885APLNR 953/4885OPRM1 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.